Abstract
Over the past three decades, the realm of monoclonal antibodies has witnessed a remarkable metamorphosis. Initially conceptualized and utilized as mere scientific instruments, these antibodies have now evolved into potent therapeutic agents, revolutionizing the landscape of modern medicine. The United States and Europe, being at the forefront of medical advancements, have embraced this transformation, with nearly 30 therapeutic monoclonal antibodies currently available in their markets. These antibodies, tailored to target specific antigens, offer a precision in treatment that was previously unattainable. This review delves into the intricate journey of monoclonal antibodies, tracing their origins, their initial applications in research, and their eventual rise as therapeutic giants. Furthermore, the paper sheds light on the challenges faced in their development, the breakthroughs that propelled their success, and the potential future innovations that could further harness their capabilities. As standing on the cusp of medical breakthroughs, understanding the past and potential future trajectories of monoclonal antibodies becomes paramount.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
